Skip to Main Content
Back to News

Lobbying Update: $30,000 of ENOVIS lobbying was just disclosed

None

$30,000 of ENOVIS lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Medicare DME Competitive Bidding reforms and refinements, prior authorization reforms - legislative and regulatory, and Implementation of the No Pain Act"

You can find more data on corporate lobbying on Quiver Quantitative.

ENOV Insider Trading Activity

ENOV Insider Trades

ENOV insiders have traded $ENOV stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:

  • DANIEL A PRYOR (EVP, Strategy & Business Dev.) purchased 10,000 shares for an estimated $289,000
  • DAMIEN MCDONALD (Chief Executive Officer) purchased 6,457 shares for an estimated $199,973
  • BRADLEY J TANDY (SVP and Chief Legal Officer) purchased 3,200 shares for an estimated $100,512
  • PHILLIP BENJAMIN (BEN) BERRY (SVP, Chief Financial Officer) purchased 2,500 shares for an estimated $74,275

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

ENOV Hedge Fund Activity

We have seen 164 institutional investors add shares of ENOV stock to their portfolio, and 142 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

ENOV Analyst Ratings

Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Wells Fargo issued a "Overweight" rating on 08/08/2025
  • UBS issued a "Buy" rating on 08/08/2025
  • Canaccord Genuity issued a "Buy" rating on 08/08/2025
  • Needham issued a "Buy" rating on 08/07/2025
  • JMP Securities issued a "Market Outperform" rating on 05/09/2025

To track analyst ratings and price targets for ENOV, check out Quiver Quantitative's $ENOV forecast page.

ENOV Price Targets

Multiple analysts have issued price targets for $ENOV recently. We have seen 6 analysts offer price targets for $ENOV in the last 6 months, with a median target of $52.0.

Here are some recent targets:

  • Danielle Antalffy from UBS set a target price of $57.0 on 08/08/2025
  • Caitlin Cronin from Canaccord Genuity set a target price of $58.0 on 08/08/2025
  • Vik Chopra from Wells Fargo set a target price of $41.0 on 08/08/2025
  • Mike Matson from Needham set a target price of $49.0 on 08/07/2025
  • Vijay Kumar from Evercore ISI Group set a target price of $46.0 on 07/08/2025
  • David Turkaly from JMP Securities set a target price of $55.0 on 05/09/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles